

B2

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |  |  |   |
|--|--|--|---|
| (51) International Patent Classification <sup>6</sup> :<br>C12N 9/00, C12P 13/00   |  | A1   | (11) International Publication Number: WO 99/53035              |
|  |  |  | (43) International Publication Date: 21 October 1999 (21.10.99) |
| (21) International Application Number: PCT/US99/08014<br>(22) International Filing Date: 13 April 1999 (13.04.99)<br><br>(30) Priority Data:<br>60/081,598                      13 April 1998 (13.04.98)                      US<br>60/082,850                      23 April 1998 (23.04.98)                      US<br><br>(71) Applicant (for all designated States except US): THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. [US/US]; Boyd Graduate Studies Research Center, Athens, GA 30602-7411 (US).<br><br>(72) Inventors; and<br>(75) Inventors/Applicants (for US only): GOKARN, Ravi, R. [IN/US]; 14300 34th Avenue North #209, Plymouth, MN 55447 (US). EITEMAN, Mark, A. [US/US]; 111 Riverbottom Way, Athens, GA 30606 (US). ALTMAN, Elliot [US/US]; 210 Great Oak Drive, Athens, GA 30605 (US).<br><br>(74) Agent: SANDBERG, Victoria, A.; Muetting, Raasch & Gebhardt, P.A., P.O. Box 581415, Minneapolis, MN 55458-1415 (US). |  | (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).<br><br>Published<br>With international search report.<br>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. |   |
| (54) Title: PYRUVATE CARBOXYLASE OVEREXPRESSION FOR ENHANCED PRODUCTION OF OXALOACETATE-DERIVED BIOCHEMICALS IN MICROBIAL CELLS  |  |  |   |
| (57) Abstract  |  |  |   |
| Metabolic engineering is used to increase the carbon flow toward oxaloacetate to enhance production of bulk biochemicals, such as lysine and succinate, in bacterial fermentations. Carbon flow is redirected by genetically engineering the cells to overexpress the enzyme pyruvate carboxylase.   |  |  |   |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   | ML | Mali   | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | MN | Mongolia                                     | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MR | Mauritania                                   | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MW | Malawi                                       | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MX | Mexico                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | NE | Niger  | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NL | Netherlands                                  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NO | Norway                                       | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NZ | New Zealand                                  | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | PL | Poland                                       |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CN | China                    | KZ | Kazakhstan                               | RO | Romania                                      |    |                          |
| CU | Cuba                     | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| CZ | Czech Republic           | LJ | Liechtenstein                            | SD | Sudan  |    |                          |
| DE | Germany                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| DK | Denmark                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |
| EE | Estonia                  |    |  |    |  |    |                          |

PYRUVATE CARBOXYLASE OVEREXPRESSION FOR ENHANCED PRODUCTION OF OXALOACETATE-  
DERIVED BIOCHEMICALS IN MICROBIAL CELLS

5

**Background of the Invention**

Tremendous commercial potential exists for producing oxaloacetate-derived biochemicals via aerobic or anaerobic bacterial fermentation processes. Aerobic fermentation processes can be used to produce oxaloacetate-derived amino acids such as asparagine, aspartate, methionine, threonine, isoleucine, and lysine. Lysine, in particular, is of great commercial interest in the world market. Raw materials comprise a significant portion of lysine production cost, and hence process yield (product generated per substrate consumed) is an important measure of performance and economic viability. The stringent metabolic regulation of carbon flow (described below) can limit process yields. Carbon flux towards oxaloacetate (OAA) remains constant regardless of system perturbations (J. Vallino et al., Biotechnol. Bioeng., 41, 633-646 (1993)). In one reported fermentation, to maintain this rigid regulation of carbon flow at the low growth rates desirable for lysine production, the cells converted less carbon to oxaloacetate, thereby limiting the lysine yield (R. Kiss et al., Biotechnol. Bioeng., 39, 565-574 (1992)). Hence, a tremendous opportunity exists to improve the process by overcoming the metabolic regulation of carbon flow.

Anaerobic fermentation processes can be used to produce oxaloacetate-derived organic acids such as malate, fumarate, and succinate. Chemical processes using petroleum feedstock can also be used, and have historically been more efficient for production of these organic acids than bacterial fermentations. Succinic acid in particular, and its derivatives, have great potential for use as specialty chemicals. They can be advantageously employed in diverse applications in the food, pharmaceutical, and cosmetics

industries, and can also serve as starting materials in the production of commodity chemicals such as 1,4-butanediol and tetrahydrofuran (L. Schilling, FEMS Microbiol. Rev., 16, 101-110 (1995)). Anaerobic rumen bacteria have been considered for use in producing succinic acid via bacterial fermentation processes, but these bacteria tend to lyse during the fermentation. More recently, the strict anaerobe *Anaerobiospirillum succiniciproducens* has been used, which is more robust and produces higher levels of succinate (R. Datta, U. S. Patent 5,143,833 (1992); R. Datta et al., Eur. Pat. Appl. 405707 (1990)).

Commercial fermentation processes use crop-derived carbohydrates to produce bulk biochemicals. Glucose, one common carbohydrate substrate, is usually metabolized via the Embden-Meyerhof-Parnas (EMP) pathway, also known as the glycolytic pathway, to phosphoenolpyruvate (PEP) and then pyruvate. All organisms derive some energy from the glycolytic breakdown of glucose, regardless of whether they are grown aerobically or anaerobically. However, beyond these two intermediates, the pathways for carbon metabolism are different depending on whether the organism grows aerobically or anaerobically, and the fates of PEP and pyruvate depend on the particular organism involved as well as the conditions under which metabolism is taking place.

In aerobic metabolism, the carbon atoms of glucose are oxidized fully to carbon dioxide in a cyclic process known as the tricarboxylic acid (TCA) cycle or, sometimes, the citric acid cycle, or Krebs cycle. The TCA cycle begins when oxaloacetate combines with acetyl-CoA to form citrate. Complete oxidation of glucose during the TCA cycle ultimately liberates significantly more energy from a single molecule of glucose than is extracted during glycolysis alone. In addition to fueling the TCA cycle in aerobic fermentations, oxaloacetate also serves as an important precursor for the synthesis of the amino acids asparagine, aspartate, methionine, threonine, isoleucine and lysine. This aerobic pathway is shown in Fig. 1 for *Escherichia coli*, the most commonly studied microorganism. Anaerobic organisms, on the other hand, do not fully oxidize glucose. Instead, pyruvate and oxaloacetate are used as acceptor

molecules in the reoxidation of reduced cofactors (NADH) generated in the EMP pathway. This leads to the generation and accumulation of reduced biochemicals such as acetate, lactate, ethanol, formate and succinate. This anaerobic pathway for *E. coli* is shown in Fig. 2.

5 Intermediates of the TCA cycle are also used in the biosynthesis of many important cellular compounds. For example,  $\alpha$ -ketoglutarate is used to biosynthesize the amino acids glutamate, glutamine, arginine, and proline, and succinyl-CoA is used to biosynthesize porphyrins. Under anaerobic conditions, these important intermediates are still needed. As a result, succinyl-CoA, for  
10 example, is made under anaerobic conditions from oxaloacetate in a reverse reaction; i.e., the TCA cycle runs backwards from oxaloacetate to succinyl-CoA.

Oxaloacetate that is used for the biosynthesis of these compounds must be replenished if the TCA cycle is to continue unabated and metabolic functionality is to be maintained. Many organisms have thus developed what are  
15 known as "anaplerotic pathways" that regenerate intermediates for recruitment into the TCA cycle. Among the important reactions that accomplish this replenishing are those in which oxaloacetate is formed from either PEP or pyruvate. These pathways that resupply intermediates in the TCA cycle can be utilized during either aerobic or anaerobic metabolism.

20 PEP occupies a central position, or node, in carbohydrate metabolism. As the final intermediate in glycolysis, and hence the immediate precursor in the formation of pyruvate via the action of the enzyme pyruvate kinase, it can serve as a source of energy. Additionally, PEP can replenish intermediates in the TCA cycle via the anaplerotic action of the enzyme PEP  
25 carboxylase, which converts PEP directly into the TCA intermediate oxaloacetate. PEP is also often a cosubstrate for glucose uptake into the cell via the phosphotransferase system (PTS) and is used to biosynthesize aromatic amino acids. In many organisms, TCA cycle intermediates can be regenerated directly from pyruvate. For example, pyruvate carboxylase (PYC), which is  
30 found in some bacteria but not *E. coli*, mediates the formation of oxaloacetate by the carboxylation of pyruvate utilizing carboxybiotin. As might be expected, the

partitioning of PEP is rigidly regulated by cellular control mechanisms, causing a metabolic "bottleneck" which limits the amount and direction of carbon flowing through this juncture. The enzyme-mediated conversions that occur between PEP, pyruvate and oxaloacetate are shown in Fig. 3.

5 TCA cycle intermediates can also be regenerated in some plants and microorganisms from acetyl-CoA via what is known as the "glyoxylate shunt," "glyoxylate bypass" or glyoxylate cycle (Fig. 4). This pathway enables organisms growing on 2-carbon substrates to replenish their oxaloacetate. Examples of 2-carbon substrates include acetate and other fatty acids as well as  
10 long-chain n-alkanes. These substrates do not provide a 3-carbon intermediate such as PEP which can be carboxylated to form oxaloacetate. In the glyoxylate shunt, isocitrate from the TCA cycle is cleaved into glyoxylate and succinate by the enzyme isocitrate lyase. The released glyoxylate combines with acetyl-CoA to form malate through the action of the enzyme malate synthase. Both  
15 succinate and malate generate oxaloacetate through the TCA cycle. Expression of the genes encoding the glyoxylate bypass enzymes is tightly controlled, and normally these genes are repressed when 3-carbon compounds are available. In *E. coli*, for example, the genes encoding the glyoxylate bypass enzymes are located on the *aceBAK* operon and are controlled by several transcriptional  
20 regulators: *iclR* (A. Sunnarborg et al., *J. Bacteriol.*, 163, 2642-2649 (1990)), *fadR* (W. Nunn et al., *J. Bacteriol.*, 148, 83-90 (1981)), *fruR* (A. Chia et al., *J. Bacteriol.*, 171, 2424-2434 (1989)), and *arcAB* (S. Iuchi et al., *J. Bacteriol.*, 171, 868-873 (1989); S. Iuchi et al., *Proc. Natl. Acad. Sci. USA*, 85, 1888-1892 (1988)). The glyoxylate bypass enzymes are not expressed when *E. coli* is  
25 grown on glucose, glycerol, or pyruvate as a carbon source. The glyoxylate shunt is induced by fatty acids such as acetate (Kornberg, *Biochem. J.*, 99, 1-11 (1966)).

Various metabolic engineering strategies have been pursued, with little success, in an effort to overcome the network rigidity that surrounds carbon  
30 metabolism. For example, overexpression of the native enzyme PEP carboxylase in *E. coli* was shown to increase the carbon flux towards

oxaloacetate (C. Millard et al., Appl. Environ. Microbiol., 62, 1808-1810 (1996); W. Farmer et al, Appl. Env. Microbiol., 63, 3205-3210 (1997)); however, such genetic manipulations also cause a decrease in glucose uptake (P. Chao et al., Appl. Env. Microbiol., 59, 4261-4265 (1993)), since PEP is a required cosubstrate for glucose transport via the phosphotransferase system. An attempt to improve lysine biosynthesis in *Corynebacterium glutamicum* by overexpressing PEP carboxylase was likewise not successful (J. Cremer et al., Appl. Env. Microbiol., 57, 1746-1752 (1991)). In another approach to divert carbon flow toward oxaloacetate, the glyoxylate shunt in *E. coli* was derepressed by knocking out one of the transcriptional regulators, *fadR*. Only a slight increase in biochemicals derived from oxaloacetate was observed (W. Farmer et al.; Appl. Environ. Microbiol., 63, 3205-3210 (1997)). In a different approach, malic enzyme from *Ascaris suum* was overproduced in mutant *E. coli* which were deficient for the enzymes that convert pyruvate to lactate, acetyl-CoA, and formate. This caused pyruvate to be converted to malate which increased succinate production (see Fig. 2). However, this approach is problematic, since the mutant strain in question cannot grow under the strict anaerobic conditions which are required for the optimal fermentation of glucose to organic acids (L. Stols et al., Appl. Biochem. Biotechnol., 63-65, 153-158 (1997)).

A metabolic engineering approach that successfully overcomes the network rigidity that characterizes carbon metabolism and diverts more carbon toward oxaloacetate, thereby increasing the yields of oxaloacetate-derived biochemicals per amount of added glucose, would represent a significant and long awaited advance in the field.

25

### Summary of the Invention

The present invention employs a unique metabolic engineering approach which overcomes a metabolic limitation that cells use to regulate the synthesis of the biochemical oxaloacetate. The invention utilizes metabolic engineering to divert more carbon from pyruvate to oxaloacetate by making use

30

of the enzyme pyruvate carboxylase. This feat can be accomplished by introducing a native (i.e., endogenous) and/or foreign (i.e., heterologous) nucleic acid fragment which encodes a pyruvate carboxylase into a host cell, such that a functional pyruvate carboxylase is overproduced in the cell. Alternatively, the DNA of a cell that endogenously expresses a pyruvate carboxylase can be mutated to alter transcription of the native pyruvate carboxylase gene so as to cause overproduction of the native enzyme. For example, a mutated chromosome can be obtained by employing either chemical or transposon mutagenesis and then screening for mutants with enhanced pyruvate carboxylase activity using methods that are well-known in the art. Overexpression of pyruvate carboxylase causes the flow of carbon to be preferentially diverted toward oxaloacetate and thus increases production of biochemicals which are biosynthesized from oxaloacetate as a metabolic precursor.

Accordingly, the present invention provides a metabolically engineered cell that overexpresses pyruvate carboxylase. Overexpression of pyruvate carboxylase is preferably effected by transforming the cell with a DNA fragment encoding a pyruvate carboxylase that is derived from an organism that endogenously expresses pyruvate carboxylase, such as *Rhizobium etli* or *Pseudomonas fluorescens*. Optionally, the metabolically engineered cell of the invention overexpresses PEP carboxylase in addition to pyruvate carboxylase. Also optionally, the metabolically engineered cell does not express a detectable level of PEP carboxykinase. In a particularly preferred embodiment of the invention, the metabolically engineered cell is a *C. glutamicum*, *E. coli*, *Brevibacterium flavum*, or *Brevibacterium lactofermentum* cell that expresses a heterologous pyruvate carboxylase.

The invention also includes a method for making a metabolically engineered cell that involves transforming a cell with a nucleic acid fragment that contains a nucleotide sequence encoding an enzyme having pyruvate carboxylase activity, to yield a metabolically engineered cell that overexpresses pyruvate carboxylase. The method optionally includes co-transforming the cell with a nucleic acid fragment that contains a nucleotide sequence encoding an



enzyme having PEP carboxylase activity so that the metabolically engineered cells also overexpress PEP carboxylase.

Also included in the invention is a method for making an oxaloacetate-derived biochemical that includes providing a cell that produces the biochemical; transforming the cell with a nucleic acid fragment containing a nucleotide sequence encoding an enzyme having pyruvate carboxylase activity; expressing the enzyme in the cell to cause increased production of the biochemical; and isolating the biochemical from the cell. Preferred biochemicals having oxaloacetate as a metabolic precursor include, but are not limited to, amino acids such as lysine, asparagine, aspartate, methionine, threonine, and isoleucine; organic acids such as succinate, malate and fumarate; pyrimidine nucleotides; and porphyrins.

The invention further includes a nucleic acid fragment isolated from *P. fluorescens* which contains a nucleotide sequence encoding a pyruvate carboxylase enzyme, preferably the  $\alpha 4\beta 4$  pyruvate carboxylase enzyme produced by *P. fluorescens*.

#### **Brief Description of the Drawings**

Figure 1. Aerobic pathway in *E. coli* depicting glycolysis, the TCA cycle, and biosynthesis of oxaloacetate-derived biochemicals; dashed lines signify that multiple steps are required to biosynthesize the compound while solid lines signify a one-step conversion; the participation of PEP in glucose uptake is shown by a light line; the pathway as shown is not stoichiometric, nor does it include cofactors.

Figure 2. Anaerobic pathway in *E. coli* depicting glycolysis and biosynthesis of selected oxaloacetate-derived biochemicals; the participation of PEP in glucose uptake is shown by the dashed line; the pathway as shown is not stoichiometric, nor does it include all cofactors.

Figure 3. Biosynthetic pathways that directly regulate the intracellular levels of oxaloacetate; not all organisms contain all of these enzymes; *E. coli*, for example, does not contain pyruvate carboxylase.

Figure 4. The TCA cycle, showing entry into the cycle of 3-carbon intermediates and also including the glyoxylate shunt for 2-carbon intermediates (darker arrows).

Figure 5. Kinetic analysis of pyruvate carboxylase activities for MG1655 pUC18 (○) and MG1655 pUC18-*pyc* (●) with respect to pyruvate.

Figure 6. Effects of increasing aspartate concentrations on the activity of pyruvate carboxylase.

Figure 7. Kinetic analysis of pyruvate carboxylase with respect to ATP and ADP; pyruvate carboxylase activity was determined in the absence of ADP (●) and in the presence of 1.5 mM ADP (○).

Figure 8. Growth of a *ppc* null *E. coli* strain which contains either pUC18 or the pUC18-*pyc* construct on minimal media that utilizes glucose as a sole carbon source.

Figure 9. Effect of nicotinamide nucleotides on pyruvate carboxylase activity: NADH (○), NAD<sup>+</sup> (□), NADPH (Δ) and NADP<sup>+</sup> (◇).

Figure 10. Growth pattern and selected fermentation products of wild-type strain (MG1655) under strict anaerobic conditions in a glucose-limited (10 g/L) medium; concentrations of glucose (●), succinate (■), lactate (○), formate (□) and dry cell mass (Δ) were measured.

Figure 11. Growth pattern and selected fermentation products of wild-type strain with pUC18 cloning/expression vector (MG1655/pUC18) under strict anaerobic conditions in a glucose-limited (10 g/L) medium; concentrations of glucose (●), succinate (■), lactate (○), formate (□) and dry cell mass (Δ) were measured.

Figure 12. Growth pattern and selected fermentation products of wild-type strain with *pyc* gene (MG1655/pUC18-*pyc*) under strict anaerobic conditions in a glucose-limited (10 g/L) medium; concentrations of glucose (●), succinate (■), lactate (○), formate (□) and dry cell mass (Δ) were measured.

Figure 13. Growth pattern and threonine production in the threonine producing strain  $\beta$ IM-4 (ATCC 21277) containing either pTrc99A or pTrc99A-pyc under strict aerobic conditions in a glucose-limited (30 g/L) medium; optical density in the pTrc99A containing strain (○), optical density in the pTrc99A-pyc containing strain (□), threonine concentrations in the pTrc99A containing strain (●), and threonine concentrations in the pTrc99A-pyc containing strain (■) were measured.

### Detailed Description of the Invention

10

Metabolic engineering involves genetically overexpressing particular enzymes at critical points in a metabolic pathway, and/or blocking the synthesis of other enzymes, to overcome or circumvent metabolic "bottlenecks." The goal of metabolic engineering is to optimize the rate and conversion of a substrate into a desired product. The present invention employs a unique metabolic engineering approach which overcomes a metabolic limitation that cells use to regulate the synthesis of the biochemical oxaloacetate. Specifically, cells of the present invention are genetically engineered to overexpress a functional pyruvate carboxylase, resulting in increased levels of oxaloacetate.

20

Genetically engineered cells are referred to herein as "metabolically engineered" cells when the genetic engineering is directed to disruption or alteration of a metabolic pathway so as to cause a change in the metabolism of carbon. An enzyme is "overexpressed" in a metabolically engineered cell when the enzyme is expressed in the metabolically engineered cell at a level higher than the level at which it is expressed in a comparable wild-type cell. In cells that do not endogenously express a particular enzyme, any level of expression of that enzyme in the cell is deemed an "overexpression" of that enzyme for purposes of the present invention.

25

Many organisms can synthesize oxaloacetate from either PEP via the enzyme PEP carboxylase, or from pyruvate via the biotin-dependent enzyme pyruvate carboxylase. Representatives of this class of organisms include *C.*

30

*glutamicum*, *R. etli*, *P. fluorescens*, *Pseudomonas citronellolis*, *Azotobacter vinelandii*, *Aspergillus nidulans*, and rat liver cells. Other organisms cannot synthesize oxaloacetate directly from pyruvate because they lack the enzyme pyruvate carboxylase. *E. coli*, *Fibrobacter succinogenes*, and *Ruminococcus* 5 *flaveflaciens* are representatives of this class of organisms. In either case, the metabolic engineering approach of the present invention can be used to redirect carbon to oxaloacetate and, as a result, enhance the production of biochemicals which use oxaloacetate as a metabolic precursor.

The cell that is metabolically engineered according to the 10 invention is not limited in any way to any particular type or class of cell. It can be a eukaryotic cell or a prokaryotic cell; it can include, but is not limited to, a cell of a human, animal, plant, insect, yeast, protozoan, bacterium, or archaeobacterium. Preferably, the cell is a microbial cell, more preferably, a bacterial cell. Advantageously, the bacterial cell can be an *E. coli*, *C. glutamicum*, *B. flavum* or *B. lactofermentum* cell; these strains are currently 15 being employed industrially to make amino acids which can be derived from oxaloacetate using bacterial fermentation processes. Mutant *E. coli* strains are currently being considered for commercial synthesis of succinate via anaerobic fermentation (L. Stols et al., Appl. Environ. Microbiol., 63, 2695-2701 (1997); 20 L. Stols et al., Appl. Biochem. Biotech., 63, 153-158 (1997)), although *A. succiniciproducens* has been considered in the past. Rhizopus fungi are now being considered to produce fumarate via aerobic fermentations (N. Cao, Appl. Biochem. Biotechnol., 63, 387-394 (1997); J. Du et al., Appl. Biochem. Biotech., 63, 541-556 (1997)). Bacteria that lack endogenous pyruvate 25 carboxylase, such as *E. coli*, *Fibrobacter succinogenes*, and *R. flaveflaciens*, can be used in the metabolic engineering strategy described by the invention.

Optionally, the metabolically engineered cell has been engineered to disrupt, block, attenuate or inactivate one or more metabolic pathways that draw carbon away from oxaloacetate. For example, alanine and valine can 30 typically be biosynthesized directly from pyruvate, and by inactivating the

enzymes involved in the synthesis of either or both of these amino acids, oxaloacetate production can be increased. Thus, the metabolically engineered cell of the invention can be an alanine and/or a valine auxotroph, more preferably a *C. glutamicum* alanine and/or a valine auxotroph. Likewise, the  
5 metabolically engineered cell can be engineered to reduce or eliminate the production of PEP carboxykinase, which catalyzes the formation of PEP from oxaloacetate (the reverse of the reaction catalyzed by PEP carboxylase). Preventing or reducing the expression of a functional PEP carboxykinase will result in more carbon shunted to oxaloacetate and hence the amino acids and  
10 organic acids biosynthesized therefrom.

Another alternative involves interfering with the metabolic pathway used to produce acetate from acetyl CoA. Disrupting this pathway should result in higher levels of acetyl CoA, which may then indirectly result in increased amounts of oxaloacetate. Moreover, where the pyruvate carboxylase  
15 enzyme that is expressed in the metabolically engineered cell is one that is activated by acetyl CoA (see below), higher levels of acetyl CoA in these mutants lead to increased activity of the enzyme, causing additional carbon to flow from pyruvate to oxaloacetate. Thus, acetate<sup>-</sup> mutants are preferred metabolically engineered cells.

20 The pyruvate carboxylase expressed by the metabolically engineered cell can be either endogenous or heterologous. A "heterologous" enzyme is one that is encoded by a nucleotide sequence that is not normally present in the cell. For example, a bacterial cell that has been transformed with and expresses a gene from a different species or genus that encodes a pyruvate carboxylase contains a  
25 heterologous pyruvate carboxylase. The heterologous nucleic acid fragment may or may not be integrated into the host genome. The term "pyruvate carboxylase" means a molecule that has pyruvate carboxylase activity; i.e., that is able to catalyze carboxylation of pyruvate to yield oxaloacetate. The term "pyruvate carboxylase" thus includes naturally occurring pyruvate carboxylase enzymes, along with  
30 fragments, derivatives, or other chemical, enzymatic or structural modifications thereof, including enzymes encoded by insertion, deletion or site mutants of naturally

occurring pyruvate carboxylase genes, as long as pyruvate carboxylase activity is retained. Pyruvate carboxylase enzymes and, in some cases, genes that have been characterized include human pyruvate carboxylase (GenBank K02282; S. Freytag et al., J. Biol. Chem., 259, 12831-12837 (1984)); pyruvate carboxylase from

5 *Saccharomyces cerevisiae* (GenBank X59890, J03889, and M16595; R. Stucka et al., Mol. Gen. Genet., 229, 305-315 (1991); F. Lim et al., J. Biol. Chem., 263, 11493-11497 (1988); D. Myers et al., Biochemistry, 22, 5090-5096 (1983)); pyruvate carboxylase from *Schizosaccharomyces pombe* (Gen bank D78170); pyruvate carboxylase from *R. etli* (GenBank U51439; M. Dunn et al., J. Bacteriol., 178, 5960-

10 5070 (1996)); pyruvate carboxylase from *Rattus norvegicus* (GenBank U81515; S. Jitrapakdee et al., J. Biol. Chem., 272, 20522-20530 (1997)); pyruvate carboxylase from *Bacillus stearothermophilus* (GenBank D83706; H. Kondo, Gene, 191, 47-50 (1997); S. Libor, Biochemistry, 18, 3647-3653 (1979)); pyruvate carboxylase from *P. fluorescens* (R. Silvia et al., J. Gen. Microbiol., 93, 75-81 (1976); and pyruvate

15 carboxylase from *C. glutamicum* (GenBank Y09548).

Preferably, the pyruvate carboxylase expressed by the metabolically engineered cells is derived from either *R. etli* or *P. fluorescens*. The pyruvate carboxylase in *R. etli* is encoded by the *pyc* gene (M. Dunn et al., J. Bacteriol., 178, 5960-5970 (1996)). The *R. etli* enzyme is classified as an  $\alpha 4$  pyruvate carboxylase,

20 which is inhibited by aspartate and requires acetyl CoA for activation. Members of this class of pyruvate carboxylases might not seem particularly well-suited for use in the present invention, since redirecting carbon flow from pyruvate to oxaloacetate would be expected to cause reduced production of acetyl CoA, and increased production of aspartate, both of which will decrease pyruvate carboxylase activity.

25 However, expression of *R. etli* pyruvate carboxylase in a bacterial host is shown herein to be effective to increase production of oxaloacetate and its downstream metabolites (see Examples I and II). Moreover, this can be accomplished without adversely affecting glucose uptake by the host (see Example III) which has been the stumbling block in previous efforts to divert carbon to oxaloacetate by

overexpressing PEP carboxylase (P. Chao et al., Appl. Env. Microbiol., 59, 4261-4265 (1993)).

In a particularly preferred embodiment, the metabolically engineered cell expresses an  $\alpha 4\beta 4$  pyruvate carboxylase. Members of this class of pyruvate carboxylases do not require acetyl CoA for activation, nor are they inhibited by aspartate, rendering them particularly well-suited for use in the present invention. *P. fluorescens* is one organism known to express an  $\alpha 4\beta 4$  pyruvate carboxylase. The metabolically engineered cell of the invention therefore is preferably one that has been transformed with a nucleic acid fragment isolated from *P. fluorescens* which contains a nucleotide sequence encoding a pyruvate carboxylase expressed therein, more preferably the pyruvate carboxylase isolated and described in R. Silvia et al., J. Gen. Microbiol., 93, 75-81 (1976), which is incorporated herein by reference, in its entirety.

Accordingly, the invention also includes a nucleic acid fragment isolated from *P. fluorescens* which includes a nucleotide sequence encoding a pyruvate carboxylase, more preferably a nucleotide sequence that encodes the pyruvate carboxylase isolated and described in R. Silvia et al., J. Gen. Microbiol., 93, 75-81 (1976).

The metabolically engineered cell of the invention is made by transforming a host cell with a nucleic acid fragment comprising a nucleotide sequence encoding an enzyme having pyruvate carboxylase activity. Methods of transformation for bacteria, plant, and animal cells are well known in the art. Common bacterial transformation methods include electroporation and chemical modification. Transformation yields a metabolically engineered cell that overexpresses pyruvate carboxylase. The preferred cells and pyruvate carboxylase enzymes are as described above in connection with the metabolically engineered cell of the invention. Optionally, the cells are further transformed with a nucleic acid fragment comprising a nucleotide sequence encoding an enzyme having PEP carboxylase activity to yield a metabolically engineered cell that also overexpresses pyruvate carboxylase, also as described above. The invention is to be broadly

understood as including methods of making the various embodiments of the metabolically engineered cells of the invention described herein.

Preferably, the nucleic acid fragment is introduced into the cell using a vector, although "naked DNA" can also be used. The nucleic acid fragment can be circular or linear, single-stranded or double stranded, and can be DNA, RNA, or any modification or combination thereof. The vector can be a plasmid, a viral vector or a cosmid. Selection of a vector or plasmid backbone depends upon a variety of desired characteristics in the resulting construct, such as a selection marker, plasmid reproduction rate, and the like. Suitable plasmids for expression in *E. coli*, for example, include pUC(X), pKK223-3, pKK233-2, pTrc99A, and pET-(X) wherein (X) denotes a vector family in which numerous constructs are available. pUC(X) vectors can be obtained from Pharmacia Biotech (Piscataway, NH) or Sigma Chemical Co. (St. Louis, MO). pKK223-3, pKK233-2 and pTrc99A can be obtained from Pharmacia Biotech. pET-(X) vectors can be obtained from Promega (Madison, WI) Stratagene (La Jolla, CA) and Novagen (Madison, WI). To facilitate replication inside a host cell, the vector preferably includes an origin of replication (known as an "ori") or replicon. For example, ColE1 and P15A replicons are commonly used in plasmids that are to be propagated in *E. coli*.

The nucleic acid fragment used to transform the cell according to the invention can optionally include a promoter sequence operably linked to the nucleotide sequence encoding the enzyme to be expressed in the host cell. A promoter is a DNA fragment which causes transcription of genetic material. Transcription is the formation of an RNA chain in accordance with the genetic information contained in the DNA. The invention is not limited by the use of any particular promoter, and a wide variety are known. Promoters act as regulatory signals that bind RNA polymerase in a cell to initiate transcription of a downstream (3' direction) coding sequence. A promoter is "operably linked" to a nucleic acid sequence if it is does, or can be used to, control or regulate transcription of that nucleic acid sequence. The promoter used in the invention can be a constitutive or an inducible promoter. It can be, but need not be, heterologous with respect to the host



cell. Preferred promoters for bacterial transformation include *lac*, *lacUV5*, *tac*, *trc*, T7, SP6 and *ara*.

The nucleic acid fragment used to transform the host cell can, optionally, include a Shine Dalgarno site (e.g., a ribosome binding site) and a start  
5 site (e.g., the codon ATG) to initiate translation of the transcribed message to produce the enzyme. It can, also optionally, include a termination sequence to end translation. A termination sequence is typically a codon for which there exists no corresponding aminoacyl-tRNA, thus ending polypeptide synthesis. The nucleic acid fragment used to transform the host cell can optionally further include a transcription  
10 termination sequence. The *rrnB* terminators, which is a stretch of DNA that contains two terminators, T1 and T2, is the most commonly used terminator that is incorporated into bacterial expression systems (J. Brosius et al., *J. Mol. Biol.*, **148**, 107-127 (1981)).

The nucleic acid fragment used to transform the host cell optionally  
15 includes one or more marker sequences, which typically encode a gene product, usually an enzyme, that inactivates or otherwise detects or is detected by a compound in the growth medium. For example, the inclusion of a marker sequence can render the transformed cell resistant to an antibiotic, or it can confer compound-specific metabolism on the transformed cell. Examples of a marker sequence are sequences  
20 that confer resistance to kanamycin, ampicillin, chloramphenicol and tetracycline.

In a preferred embodiment, the host cell, preferably *E. coli*, *C. glutamicum*, *B. flavum* or *B. lactofermentum*, is transformed with a nucleic acid fragment comprising a pyruvate carboxylase gene, preferably a gene that is isolated from *R. etli* or *P. fluorescens*, more preferably the *pyc* gene from *R. etli*, such that the  
25 gene is transcribed and expressed in the host cell to cause increased production of oxaloacetate and, consequently, increased production of the downstream metabolite of interest, relative to a comparable wild-type cell.

The metabolically engineered cell of the invention overexpresses pyruvate carboxylase. Stated in another way, the metabolically engineered cell  
30 expresses pyruvate carboxylase at a level higher than the level of pyruvate carboxylase expressed in a comparable wild-type cell. This comparison can be made

in any number of ways by one of skill in the art and is done under comparable growth conditions. For example, pyruvate carboxylase activity can be quantified and compared using the method of Payne and Morris (*J. Gen. Microbiol.*, 59, 97-101 (1969)). The metabolically engineered cell that overexpresses pyruvate carboxylase will yield a greater activity than a wild-type cell in this assay. In addition, or alternatively, the amount of pyruvate carboxylase can be quantified and compared by preparing protein extracts from the cells, subjecting them to SDS-PAGE, transferring them to a Western blot, then detecting the biotinylated pyruvate carboxylase protein using detection kits which are commercial available from, for example, Pierce Chemical Company (Rockford, IL), Sigma Chemical Company (St. Louis, MO) or Boehringer Mannheim (Indianapolis, IN) for visualizing biotinylated proteins on Western blots. In some suitable host cells, pyruvate carboxylase expression in the non-engineered, wild-type cell may be below detectable levels.

Optionally, the metabolically engineered cell of the invention also overexpresses PEP carboxylase. In other words, the metabolically engineered cell optionally expresses PEP carboxylase at a level higher than the level of PEP carboxylase expressed in a comparable wild-type cell. Again, this comparison can be made in any number of ways by one of skill in the art and is done under comparable growth conditions. For example, PEP carboxylase activity can be assayed, quantified and compared. In one assay, PEP carboxylase activity is measured in the absence of ATP using PEP instead of pyruvate as the substrate, by monitoring the appearance of CoA-dependent thionitrobenzoate formation at 412 nm (see Example III). The metabolically engineered cell that overexpresses PEP carboxylase will yield a greater PEP carboxylase activity than a wild-type cell. In addition, or alternatively, the amount of PEP carboxylase can be quantified and compared by preparing protein extracts from the cells, subjecting them to SDS-PAGE, transferring them to a Western blot, then detecting the PEP carboxylase protein using PEP antibodies in conjunction with detection kits available from Pierce Chemical Company (Rockford IL), Sigma Chemical Company (St. Louis, MO) or Boehringer Mannheim (Indianapolis, IN) for visualizing antigen-antibody complexes on Western blots. In a

preferred embodiment, the metabolically engineered cell expresses PEP carboxylase derived from a cyanobacterium, more preferably *Anacystis nidulans*.

The invention further includes a method for producing an oxaloacetate-derived biochemical by enhancing or augmenting production of the biochemical in a cell that is, prior to transformation as described herein, capable of biosynthesizing the biochemical. The cell is transformed with a nucleic acid fragment comprising a nucleotide sequence encoding an enzyme having pyruvate carboxylase activity, the enzyme is expressed in the cell so as to cause increased production of the biochemical relative to a comparable, wild-type cell, and the biochemical is isolated from the cell according to known methods. The biochemicals can be isolated from the metabolically engineered cells using protocols, methods and techniques that are well-known in the art. For example, succinic acid can be isolated by electrodialysis (D. Glassner, U.S. Pat. No. 5,143,833 (1992)) or by precipitation as calcium succinate (R. Datta, U.S. Pat. No., 5,143,833 (1992)); malic acid can be isolated by electrodialysis (R. Sieipenbusch, U.S. Pat. No. 4,874,700 (1989)); lysine can be isolated by adsorption/reverse osmosis (T. Kaneko et al., U.S. Pat. No., 4,601,829 (1986)). The preferred host cells, oxaloacetate-derived biochemicals, and pyruvate carboxylase enzymes are as described herein.

The biochemicals that are produced or overproduced in, and isolated from, the metabolically engineered cells according to the method of the invention are those that are or can be metabolically derived from oxaloacetate (i.e., with respect to which oxaloacetate is a metabolic precursor). These oxaloacetate-derived biochemicals include, but are not limited to, amino acids such as lysine, asparagine, aspartate, methionine, threonine, arginine, glutamate, glutamine, proline and isoleucine; organic acids such as succinate, malate, citrate, isocitrate,  $\alpha$ -ketoglutarate, succinyl-CoA and fumarate; pyrimidine nucleotides; and porphyrins such as cytochromes, hemoglobins, chlorophylls, and the like. It is to be understood that the terms used herein to describe acids (for example, the terms succinate, aspartate, glutamate, malate, fumarate, and the like) are not meant to denote any particular ionization state of the acid, and are meant to include both protonated and unprotonated forms of the compound. For example, the terms aspartate and aspartic

acid refer to the same compound and are used interchangeably, as well as succinate and succinic acid, malate and malic acid, fumarate and fumaric acid, and so on. As is well-known in the art, the protonation state of the acid depends on the  $pK_a$  of the acidic group and the pH of the medium. At neutral pH, the acids described herein are typically unprotonated.

In a particularly preferred method, lysine and succinate are produced in and obtained from a metabolically engineered bacterial cell that expresses pyruvate carboxylase, preferably pyruvate carboxylase derived from either *R. etli* or *P. fluorescens*. The method of the invention is to be broadly understood to include the production and isolation of any or all oxaloacetate-derived biochemicals recovered or recoverable from the metabolically engineered cells of the invention, regardless of whether the biochemicals are actually synthesized from oxaloacetate in accordance with the metabolic pathways shown in Figs. 1-3 or any other presently known metabolic pathways.

Advantages of the invention are illustrated by the following examples. However, the particular materials and amounts thereof recited in these examples, as well as other conditions and details, are to be interpreted to apply broadly in the art and should not be construed to unduly restrict or limit the invention in any way.

**Example 1: Expression of the *R. etli* Pyruvate Carboxylase Enzyme  
Enables *E. coli* to Convert Pyruvate to Oxaloacetate**

**MATERIALS AND METHODS**

**Bacterial strains, plasmids and growth conditions.** The bacterial strains and plasmids used in this study are listed in Table 1. *E. coli* strains were grown in LB Miller broth (rich) or M9 minimal media (J. Miller, Experiments in Molecular Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1972)). Strains carrying a plasmid were supplemented with the appropriate antibiotic to detect the

marker gene; ampicillin was used at 100  $\mu\text{g/ml}$  in rich media and 50  $\mu\text{g/ml}$  in minimal media while chloramphenicol was used at 20  $\mu\text{g/ml}$  in rich media and 10  $\mu\text{g/ml}$  in minimal media. When isopropyl  $\beta$ -D-thiogalactopyranoside (IPTG) was used to induce the pUC18-*pyc* construct, it was added at a final concentration of 1 mM.

TABLE 1: Strains and Plasmids

|    | Strains           |  |   |
|----|-------------------|--|---|
|    | Strains           | Genotype   | Reference or source   |
| 10 | MC1061            | <i>araD139</i> $\Delta$ ( <i>araABOIC-leu</i> )7679 $\Delta$ ( <i>lac</i> )74 <i>galU galK rpsL hsr hsm+</i> | M. Casadaban et al., <u>J. Mol. Biol.</u> , <b>138</b> , 179-207 (1980)                     |
|    | ALS225            | MC1061 F' <i>lacI</i> <sup>q1</sup> Z+Y+A+   | E. Altman, University of Georgia  |
|    | MG1665            | wt   | M. Guyer et al., <u>Quant. Biol., Cold Spring Harbor Symp.</u> , <b>45</b> , 135-140 (1980) |
|    | JCL 1242          | $\Delta$ ( <i>argF-lac</i> )U169 <i>ppc::Kn</i>  | P. Chao et al., <u>Appl. Env. Microbiol.</u> , <b>59</b> , 4261-4265 (1993)                 |
| 15 | Plasmids          |  | Reference or source   |
|    | pUC18             | Amp(R), ColE1 ori  | J. Norrander et al., <u>Gene.</u> , <b>26</b> , 101-106 (1983)                              |
|    | pPC1              | Tet(R), <i>pyc</i>   | M. Dunn et al., <u>J. Bacteriol.</u> , <b>178</b> , 5960-5970 (1996)                        |
|    | pUC18- <i>pyc</i> | Amp(R), <i>pyc</i> regulated by <i>Plac</i> , ColE1 ori  | This example  |
|    | pBA11             | Cam(R), <i>birA</i> , P15A ori   | D. Barker et al., <u>J. Mol. Biol.</u> , <b>146</b> , 469-492 (1981)                        |

**Construction of pUC18-*pyc*.** The *R. elli pyc* gene, which encodes pyruvate carboxylase, was amplified using the polymerase chain reaction (PCR). Pfu polymerase (Stratagene, La Jolla, CA) was used instead of Taq polymerase and the pPC1 plasmid served as the DNA template. Primers were designed based on the published *pyc* gene sequence (M. Dunn et al., J. Bacteriol., **178**, 5960-5970 (1996)) to convert the *pyc* translational start signals to match those of the *lacZ* gene. These

primers also introduced a *KpnI* (GGTACC) restriction site at the beginning of the amplified fragment and a *BglII* (AGATCT) restriction site at the end of the amplified fragment; forward primer 5' TAC TAT GGT ACC TTA GGA AAC AGC TAT GCC CAT ATC CAA GAT ACT CGT T 3' (SEQ ID NO:1), reverse primer 5' ATT CGT  
5 ACT CAG GAT CTG AAA GAT CTA ACA GCC TGA CTT TAC ACA ATC G 3' (SEQ ID NO:2) (the *KpnI*, Shine Dalgarno, ATG start, and *BglII* sites are underlined). The resulting 3.5 kb fragment was gel isolated, restricted with *KpnI* and *BglII* and then ligated into gel isolated pUC18 DNA which had been restricted with *KpnI* and *BamHI* to form the pUC18-*pyc* construct. This construct, identified as  
10 "Plasmid in *E. coli* ALS225 pUC18-*pyc*", was deposited with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA, 20110-2209, USA, and assigned ATCC number 207111. The deposit was received by the ATCC on February 16, 1999.

**Protein gels and Western blotting.** Heat-denatured cell extracts were  
15 separated on 10% SDS-PAGE gels as per Altman et. al. (*J. Bact.*, 155, 1130-1137 (1983)) and Western blots were carried out as per Carroll and Gherardini (*Infect. Immun.*, 64, 392-398 (1996)). ALS225 *E. coli* cells containing either pUC18 or pUC18-*pyc* were grown to mid-log in rich media at 37°C both in the presence and absence of IPTG. Because ALS225 contains *lacI*<sup>q1</sup> on the F', significant induction of  
20 the pUC18-*pyc* construct should not occur unless IPTG is added. Protein extracts were prepared, subjected to SDS PAGE, and Western blotted. Proteins which had been biotinylated *in vivo* were then detected using the Sigma-Blot protein detection kit (Sigma Chemical Corp., St. Louis, MO). The instructions of the manufacturer were followed except that during the development of the western blots the protein  
25 biotinylation step was omitted, thus allowing for the detection of only those proteins which had been biotinylated *in vivo*.

**Pyruvate carboxylase (PC) enzyme assay.** For pyruvate carboxylase activity measurements, 100 mL of mid-log phase culture was harvested by centrifugation at 7,000 x g for 15 minutes at 4°C and washed with 10 mL of 100 mM  
30 Tris-Cl (pH 8.0). The cells were then resuspended in 4 mL of 100 mM Tris-Cl (pH

8.0) and subsequently subjected to cell disruption by sonication. The cell debris was removed by centrifugation at 20,000 x g for 15 minutes at 4°C. The pyruvate carboxylase activity was measured by the method of Payne and Morris (J. Gen. Microbiol., 59, 97-101 (1969)). In this assay the oxaloacetate produced by pyruvate carboxylase is converted to citrate by the addition of citrate synthase in the presence of acetyl CoA and 5,5 -dithio-bis(2-nitro-benzoate) (DTNB) (Aldrich Chemical Co.); the homotetramer pyruvate carboxylase enzyme from *R. etli* requires acetyl coenzyme A for activation. The rate of increase in absorbance at 412 nm due to the presence of CoA-dependent formation of the 5-thio-2-nitrobenzoate was monitored, first after the addition of pyruvate and then after the addition of ATP. The difference between these two rates was taken as the ATP-dependent pyruvate carboxylase activity. The concentration of reaction components per milliliter of mixture was as follows: 100 mM Tris-Cl (pH 8.0), 5 mM MgCl<sub>2</sub>·H<sub>2</sub>O, 50 mM Na HCO<sub>3</sub>, 0.1 mM acetyl CoA, 0.25 mM DTNB, and 5 units (U) of citrate synthase. Pyruvate, ATP, ADP, or aspartate, were added as specified in the Results section, below. The reaction was started by adding 50 µl of cell extract. One unit of pyruvate carboxylase activity corresponds to the formation of 1 µmol of 5-thio-2-nitrobenzoate per mg of protein per minute. All enzyme assays were performed in triplicate and a standard error of less than 10% was observed. The total protein in the cell extracts was determined by the Lowry method (O. Lowry et al., J. Biol. Chem., 193, 265-275 (1951)).

## RESULTS

**Expression of the *R. etli* pyruvate carboxylase enzyme in *E. coli*.** The *R. etli pyc* gene, which encodes pyruvate carboxylase, was PCR amplified from pPC1 and subcloned into the pUC18 cloning/expression vector as described above. Because the translational start signals of the *R. etli pyc* gene were nonoptimal (*pyc* from *R. etli* uses the rare TTA start codon as well as a short spacing distance between the Shine Dalgarno and the start codon), the translational start signals were converted to match that of the *lacZ* gene which can be expressed at high levels in *E. coli* using a variety of expression vectors. When induced cell extracts of the pUC18-*pyc* construct were assayed via western blots developed to detect biotinylated proteins, a

band of about 120 kD was detected. This value is consistent with the previously reported size assessment for the *R. etli* pyruvate carboxylase enzyme (M. Dunn et al., *J. Bacteriol.*, **178**, 5960-5970 (1996)). By comparing serial dilutions of the pyruvate carboxylase which was expressed from the pUC18-*pyc* construct with purified  
5 pyruvate carboxylase enzyme obtained commercially, it was determined that, under fully induced conditions pyruvate carboxylase from *R. etli* was being expressed at 1% of total cellular protein in *E. coli*.

**Effects of biotin and biotin holoenzyme synthase on the expression of biotinylated *R. etli* pyruvate carboxylase in *E. coli*.** Pyruvate carboxylase is a  
10 biotin-dependent enzyme, and mediates the formation of oxaloacetate by a two-step carboxylation of pyruvate. In the first reaction step, biotin is carboxylated with ATP and bicarbonate as substrates, while in the second reaction the carboxyl group from carboxybiotin is transferred to pyruvate. All pyruvate carboxylases studied to date  
15 and structure of the associated subunits can vary considerably. Pyruvate carboxylases from different bacteria have been shown to form  $\alpha_4$ , or  $\alpha_4\beta_4$  structures with the size of the  $\alpha$  subunit ranging from 65 to 130 kD. In all cases, however, the  $\alpha$  subunit of the pyruvate carboxylase enzyme has been shown to contain three catalytic domains - a biotin carboxylase domain, a transcarboxylase domain, and a biotin carboxyl carrier  
20 protein domain - which work collectively to catalyze the two-step conversion of pyruvate to oxaloacetate. In the first step, a biotin prosthetic group linked to a lysine residue is carboxylated with ATP and  $\text{HCO}_3^-$ , while in the second step, the carboxyl group is transferred to pyruvate. The biotinylation of pyruvate carboxylase occurs post-translationally and is catalyzed by the enzyme biotin holoenzyme synthase. In  
25 this experiment, *E. coli* cells containing the pUC18-*pyc* construct were grown under inducing conditions in minimal defined media which either contained no added biotin, or biotin added at 50 or 100 ng/mL. Specifically, MG1655 pUC18-*pyc* cells were grown to mid-log at 37°C in M9 media that contained varying amounts of biotin. Protein extracts were prepared, subjected to SDS PAGE, and Western blotted.  
30 Proteins which had been biotinylated *in vivo* were then detected using the Sigma-Blot



protein detection kit, as described above. MG1655 was used in this experiment because it grows significantly faster than ALS225 in minimal media. Because MG1655 does not contain *lacIq*<sup>1</sup>, maximal expression of pyruvate carboxylase could be achieved without adding IPTG. The amount of biotinylated pyruvate carboxylase that was present in each sample was quantitated using a Stratagene Eagle Eye II Still Video. The biotinylation of pyruvate carboxylase that was expressed from the pUC18-*pyc* construct was clearly affected by biotin levels. Cells that had to produce all their biotin *de novo* expressed significantly lower amounts of biotinylated protein. The addition of biotin at a final concentration of 50 ng/mL was sufficient to biotinylate all of the pyruvate carboxylase that was expressed via the pUC18-*pyc* construct.

Since the post-translational biotinylation of pyruvate carboxylase is carried out by the enzyme biotin holoenzyme synthase, the effect of excess biotin holoenzyme synthase on the biotinylation of pyruvate carboxylase was investigated. This analysis was accomplished by introducing the multicopy plasmid pBA11 (which contains the *birA* gene encoding biotin holoenzyme synthase) into *E. coli* cells that also harbored the pUC18-*pyc* construct; pBA11 is a pACYC184 derivative and thus compatible with pUC18-*pyc*. The effects of excess biotin holoenzyme synthase enzyme were examined in rich media where biotin would also be present in excess. Specifically, ALS225 cells containing pUC18-*pyc*, or pBA11 were grown to mid-log at 37°C in rich media that contained IPTG. Protein extracts were prepared, subjected to SDS PAGE, and Western blotted, and proteins which had been biotinylated *in vivo* were then detected using the Sigma-Blot protein detection kit as described above. Barker et al. (*J. Mol. Biol.*, 146, 469-492 (1981)) have shown that pBA11 causes a 12-fold increase in biotin holoenzyme synthase enzyme levels. The amount of biotinylated pyruvate carboxylase that was present in each sample was quantitated using a Stratagene Eagle Eye II Still Video System. Protein extracts prepared from cells which either contained only pUC18-*pyc* or both pUC18-*pyc* and pBA11 yielded

equal amounts of biotinylated pyruvate carboxylase protein. This result suggests that a single chromosomal copy of *birA* is sufficient to biotinylate all of the pyruvate carboxylase that is expressed when biotin is present in excess.

***R. etli* pyruvate carboxylase can convert pyruvate to oxaloacetate in *E.***

5 ***coli*.** To confirm that the expressed pyruvate carboxylase protein was enzymatically active in *E. coli*, the coupled enzyme assay developed by Payne and Morris was employed to assess pyruvate carboxylase activity (J. Payne et al., J. Gen. Microbiol., 59, 97-101 (1969)). Cell extracts containing the induced pUC18-*pyc* construct (MG1655 pUC18-*pyc*) were tested for pyruvate carboxylase activity using varying  
10 amounts of pyruvate, and compared to controls containing the pUC18 construct (MG1655 pUC18). ATP was added at a final concentration of 5 mM to the reaction mixture and pyruvate carboxylase activity was determined in the presence of increasing amounts of pyruvate. Fig. 5 shows that *E. coli* cells harboring the pUC18-*pyc* construct could indeed convert pyruvate to oxaloacetate and that the observed  
15 pyruvate carboxylase activity followed Michaelis-Menten kinetics. A Lineweaver-Burke plot of these data revealed that the saturation constant ( $K_m$ ) for expressed pyruvate carboxylase was 0.249 mM with respect to pyruvate. This value is in excellent agreement with other pyruvate carboxylase enzymes that have been studied (H. Feir et al., Can. J. Biochem., 47, 698-710 (1969); H. Modak et al., Microbiol.,  
20 141, 2619-2628 (1995); M. Scrutton et al., Arch. Biochem. Biophys., 164, 641-654 (1974)).

It is well documented that the  $\alpha_4$  pyruvate carboxylase enzymes can be inhibited by either aspartate or adenosine diphosphate (ADP). Aspartate is the first amino acid that is synthesized from oxaloacetate and ADP is liberated when pyruvate  
25 carboxylase converts pyruvate to oxaloacetate. Pyruvate carboxylase activity in the presence of each of these inhibitors was evaluated using extracts of MG1655 cells that contained the pUC18-*pyc* construct. The effect of aspartate was analyzed by adding ATP and pyruvate to the reaction mixture to final concentrations of 5 mM and 6 mM, respectively, then determining pyruvate carboxylase activity in the presence of  
30 increasing amounts of aspartate. Fig. 6 shows the pyruvate carboxylase activity that

was obtained in the presence of different concentrations of aspartate. As expected, the pyruvate carboxylase activity was inhibited by aspartate and the specific activity decreased to approximately 43% in the presence of 8 mM aspartate. The effect of ADP was analyzed by adding pyruvate to the reaction mixture to a final concentration of 5 mM, then determining pyruvate carboxylase activity in the presence of increasing amounts of ATP. Fig. 7 shows that ADP severely affected the observed pyruvate carboxylase activity and acted as a competitive inhibitor of ATP. A Lineweaver-Burke plot of these data revealed that the saturation constant ( $K_m$ ) for expressed pyruvate carboxylase was 0.193 mM with respect to ATP and that the inhibition constant for ADP was 0.142 mM. Again, these values were in excellent agreement with other pyruvate carboxylase enzymes that have been studied H. Feir et al., Can. J. Biochem., 47, 698-710 (1969); H. Modak et al., Microbiol., 141, 2619-2628 (1995); M. Scrutton et al., Arch. Biochem. Biophys., 164, 641-654 (1974)).

To show that the expression of *R. elli* pyruvate carboxylase in *E. coli* can truly divert carbon flow from pyruvate to oxaloacetate, we tested whether the pUC18-*pyc* construct could enable an *E. coli* strain which contained a *ppc* null allele (*ppc* encodes PEP carboxylase) to grow on minimal glucose media. Because *E. coli* lacks pyruvate carboxylase and thus is only able to synthesize oxaloacetate from PEP, (see Fig. 3) *E. coli* strains which contain a disrupted *ppc* gene can not grow on minimal media which utilizes glucose as the sole carbon source (P. Chao et al., Appl. Env. Microbiol., 59, 4261-4265 (1993)). The cell line used for this experiment was JCL1242 (*ppc::kan*), which contains a kanamycin resistant cassette that has been inserted into the *ppc* gene and thus does not express the PEP carboxylase enzyme. JCL1242 cells containing either pUC18 or the pUC18-*pyc* construct were patched onto minimal M9 glucose thiamine ampicillin IPTG plates and incubated at 37°C for 48 hours. As shown in Fig. 8, *E. coli* cells which contain both the *ppc* null allele and

the pUC18-*pyc* construct were able to grow on minimal glucose plates. This complementation demonstrates that a branch point can be created at the level of pyruvate which results in the rerouting of carbon flow towards oxaloacetate, and clearly shows that pyruvate carboxylase is able to divert carbon flow from pyruvate to oxaloacetate in *E. coli*.

**Example II. Expression of *R. etli* Pyruvate Carboxylase  
Causes Increased Succinate Production in *E. coli***

**MATERIALS AND METHODS**

**Bacterial strains and plasmids.** The *E. coli* strains used in this study are listed in Table 2. The lactate dehydrogenase mutant strain designated RE02 was derived from MG1655 by P1 phage transduction using *E. coli* strain NZN111 (P. Bunch et al., Microbiol., 143, 187-195 (1997)).

**TABLE 2: Strains and plasmids used.**

|    | <u>Strains</u>      |  | <u>Genotype</u>  | <u>Reference or Source</u>  |
|----|---------------------|--|--|---|
|    |                     |  |  |   |
|    | MG1655              |  | Wild type  | M. Guyer et al.,<br><u>Quant. Biol., Cold<br/>Spring Harbor Symp.</u> ,<br><u>45</u> , 135-140 (1980) |
| 20 | RE02                |  | MG1655 <i>ldh</i>  | This example  |
|    | <u>Plasmids</u>     |  | <u>Relevant Characteristics</u>  | <u>Reference or Source</u>  |
|    |                     |  |  |   |
|    | pUC18- <i>pyc</i>   |  | Amp(R), <i>pyc</i> regulated by <i>Plac</i>                                      | Example I   |
|    | pTrc99A             |  | Amp(R), <i>lacI<sup>q</sup></i> , <i>P<sub>trc</sub></i>                         | E. Amann et al., <i>Gene</i> ,<br>69:301-315 (1988)   |
| 25 | pTrc99A- <i>pyc</i> |  | Amp(R), <i>lacI<sup>q</sup></i> , <i>pyc</i> regulated by <i>P<sub>trc</sub></i> | This example  |

The *pyc* gene from *R. etli* was originally cloned under the control of the *lac* promoter (Example I). Because this promoter is subjected to catabolic repression in the presence of glucose, a 3.5 kb *XbaI-KpnI* fragment from pUC18-*pyc* was ligated into the pTrc99A expression vector which had been digested with *XbaI* and *KpnI*.

- 5 The new plasmid was designated as pTrc99A-*pyc*. This plasmid, identified as "Plasmid in *E. coli* ALS225 pTrc99A-*pyc*", was deposited with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA, 20110-2209, USA, and assigned ATCC number 207112. The deposit was received by the ATCC on February 16, 1999. In this new construct the transcription of the *pyc* gene is under  
10 the control of artificial *trc* promoter and thus is not subjected to catabolic repression in the presence of glucose.

- Media and growth conditions.** For strain construction, *E. coli* strains were grown aerobically in Luria-Bertani (LB) medium. Anaerobic fermentations were carried out in 100 mL serum bottles with 50 mL LB medium supplemented with 20  
15 g/L glucose and 40 g/L MgCO<sub>3</sub>. The fermentations were terminated at 24 hours at which point the pH values of all fermentations were approximately pH 6.7, and glucose was completely utilized. For plasmid-containing strains either ampicillin or carbenicillin was added to introduce selective pressure during the fermentation. Each of these antibiotics was introduced initially at 100 µg/mL. In one set of experiments,  
20 no additional antibiotic was added during fermentation, while in a second set of experiments an additional 50 µg/mL was added at 7 hours and 14 hours. Pyruvate carboxylase was induced by adding 1 mM IPTG. For enzyme assays cells were grown in LB medium supplemented with 20 g/L glucose and buffered with 3.2 g/L Na<sub>2</sub>CO<sub>3</sub>.

- 25 **Fermentation product analysis and enzyme assays.** Glucose, succinate, acetate, formate, lactate, pyruvate and ethanol were analyzed by high-pressure liquid chromatography (HPLC) using a Coregel 64-H ion-exclusion column (Interactive Chromatography, San Jose, CA) and a differential refractive index detector (Model 410, Waters, Milford, MA). The eluant was 4 mM H<sub>2</sub>SO<sub>4</sub> and the column was  
30 maintained at 60°C.

For enzyme activity measurements, 50 mL of mid-log phase culture were harvested by centrifugation (10000 x g for 10 minutes at 4°C) and washed with 10 mL of 100 mM Tris-HCl buffer (pH 8.0). The cells were then resuspended in 2 mL of 100 mM Tris-HCl buffer and subjected to cell disruption by sonication. Cell debris were removed by centrifugation (20000 x g for 15 minutes at 4°C). Pyruvate carboxylase activity (J. Payne et al., J. Gen. Microbiol. 59, 97-101 (1969); see also Example I), and the endogenous activities of PEP carboxylase (K. Terada et al., J. Biochem. 109, 49-54 (1991)), malate dehydrogenase and lactate dehydrogenase (P. Bunch et al., Microbiol. 143, 187-195 (1997)) were then measured. The total protein in the cell extract was determined using the Lowry method.

## RESULTS

Table 3 shows that pyruvate carboxylase activity could be detected when the pTrc99A-*pyc* construct was introduced into either wild type cells (MG1655) or wild type cells which contained a *ldh*<sup>-</sup> null mutation (RE02). The presence of IPTG did not significantly affect the expression of other important metabolic enzymes such as PEP carboxylase, lactate dehydrogenase and malate dehydrogenase.

TABLE 3: Enzyme activity in exponential phase cultures.

| Strain                     | IPTG | Pyruvate<br>carboxylase | Sp. activity ( $\mu\text{mol}/\text{min mg protein}$ ) |                          |                         |
|----------------------------|------|-------------------------|--|--------------------------|-------------------------|
|                            |      |                         | PEP<br>carboxylase                                     | Lactate<br>dehydrogenase | Malate<br>dehydrogenase |
| MG1655                     | -    | 0.00                    | 0.15   | 0.31                     | 0.06                    |
|                            | +    | 0.00                    | 0.18   | 0.38                     | 0.06                    |
| MG1655 pTrc99A- <i>pyc</i> | -    | 0.00                    | 0.15   | 0.32                     | 0.05                    |
|                            | +    | 0.22                    | 0.11   | 0.32                     | 0.05                    |
| RE02                       | -    | 0.00                    | 0.15   | 0.00                     | 0.04                    |
|                            | +    | 0.00                    | 0.13   | 0.00                     | 0.04                    |
| RE02 pTrc99A- <i>pyc</i>   | -    | 0.00                    | 0.15   | 0.00                     | 0.04                    |
|                            | +    | 0.32                    | 0.12   | 0.00                     | 0.05                    |

In order to elucidate the effect of pyruvate carboxylase expression on the distribution of the fermentation end products, several 50 mL serum bottle fermentations were conducted (see Table 4).

TABLE 4: Effect of pyruvate carboxylase on product distribution from *E. coli* glucose fermentation.

| Strain                     | Antibiotic | Mode of antibiotic addition | Pyruvate (g/L) | Succinate (g/L) | Lactate (g/L) | Formate (g/L) | Acetate (g/L) | Ethanol (g/L) |
|----------------------------|------------|-----------------------------|----------------|-----------------|---------------|---------------|---------------|---------------|
| MG1655 (wt)                | -          | -                           | 0.00 (0.00)    | 1.57 (0.17)     | 4.30(0.73)    | 4.34 (0.50)   | 3.34 (0.36)   | 2.43 (0.24)   |
| MG1655 pTrc99A- <i>pyc</i> | Amp        | 1x                          | 0.00 (0.00)    | 4.36 (0.45)     | 2.22 (0.49)   | 3.05 (0.57)   | 3.51 (0.03)   | 2.27 (0.30)   |
| MG1655 pTrc99A- <i>pyc</i> | Car        | 1x                          | 0.00 (0.00)    | 4.42(0.44)      | 2.38 (0.76)   | 2.94 (0.46)   | 3.11 (0.36)   | 2.27(0.36)    |
| MG1655pTrc99A- <i>pyc</i>  | Amp        | 3x                          | 0.00 (0.00)    | 4.41 (0.07)     | 1.65(0.08)    | 4.17 (0.15)   | 3.93 (0.11)   | 2.91 (0.34)   |
| MG1655 pTrc99A- <i>pyc</i> | Car        | 3x                          | 0.00 (0.00)    | 4.37 (0.06)     | 1.84 (0.07)   | 4.09 (0.08)   | 3.88 (0.06)   | 2.58 (0.09)   |
| RE02 ( <i>ldh</i> -)       | -          | -                           | 0.61 (0.06)    | 1.73 (0.12)     | 0.00 (0.00)   | 6.37 (0.46)   | 4.12 (0.30)   | 3.10 (0.26)   |
| RE02 pTrc99A- <i>pyc</i>   | Amp        | 1x                          | 0.33 (0.11)    | 2.92 (0.12)     | 0.00 (0.00)   | 5.38 (0.12)   | 4.09 (0.16)   | 2.53 (0.03)   |
| RE02 pTrc99A- <i>pyc</i>   | Car        | 1x                          | 0.25 (0.05)    | 2.99 (0.55)     | 0.00 (0.00)   | 5.50 (0.90)   | 4.23 (0.71)   | 2.50 (0.44)   |
| RE02pTrc99A- <i>pyc</i>    | Amp        | 3x                          | 0.30 (0.04)    | 2.74 (0.07)     | 0.00 (0.00)   | 6.48 (0.04)   | 4.75(0.06)    | 2.99 (0.03)   |
| RE02 pTrc99A- <i>pyc</i>   | Car        | 3x                          | 0.33 (0.04)    | 2.65 (0.05)     | 0.00 (0.00)   | 6.21 (0.18)   | 4.60(0.12)    | 3.05 (0.07)   |

Antibiotics were either added once at 0 hours at a concentration of 100  $\mu\text{g/mL}$  (1x) or added at 0 hours at a concentration of 100  $\mu\text{g/mL}$  and again at 7 hours and 14 hours at 50  $\mu\text{g/mL}$  (3x). Values are the mean of three replicates and standard deviations are shown in parentheses. To calculate the net yield of each product per gram of glucose consumed, the final product concentration is divided by 20g/L of glucose.



As shown in Table 4, expression of pyruvate carboxylase caused a significant increase in succinate production in both MG1655 (wild type) and RE02 (*ldh<sup>-</sup>*). With MG1655 the induction of pyruvate carboxylase increased the production of succinate 2.7-fold from 1.57 g/L in the control strain to 4.36 g/L, thus making succinate the major product of glucose fermentation. This increase in succinate was accompanied by decreased lactate and formate formation, indicating that carbon was diverted away from lactate toward succinate formation. A similar carbon diversion from lactate toward succinate was achieved previously by the overexpression of native PEP carboxylase (C. Millard et al., Appl. Environ. Microbiol., 62, 1808-1810 (1996)). Table 4 also shows that ampicillin and carbenicillin were equally effective in maintaining sufficient selective pressure, and that the addition of more of either antibiotic during the fermentation did not further enhance the succinate production. This evidence indicates that an initial dose (of 100 µg/mL) is sufficient to maintain selective pressure throughout the fermentation, a result which might be due to the relatively high final pH (6.8) observed in our fermentation studies versus the final pH (6.0) observed in previous studies (C. Millard et al., Appl. Environ. Microbiol., 62, 1808-1810 (1996)).

Because introducing pyruvate carboxylase into *E. coli* was so successful at directing more carbon to the succinate branch, we were also interested in determining whether additional carbon could be directed to succinate by eliminating lactate dehydrogenase, since this enzyme also competes for pyruvate. Table 4 compares the results of fermentations using the RE02 (*ldh<sup>-</sup>*) strain with or without the pTrc99A-*pyc* plasmid. Compared to the wild type strain (MG1655), the RE02 strain showed no significant change in succinate production. Instead, fermentations with the RE02 strain, whether it contained the pTrc99A-*pyc* plasmid or not, resulted in increased formate, acetate and ethanol production, accompanied by secretion of pyruvate. The fact that pyruvate was secreted into the fermentation broth indicates that the rate of

glycolysis was greater than the rate of pyruvate utilization. The observed increase in formate concentrations in the *ldh<sup>-</sup>* mutant may be caused by the accumulation of pyruvate, a compound which is known to exert a positive allosteric effect on pyruvate formate lyase (G. Sawers et al., J. Bacteriol., 170, 5330-5336 (1988)). With RE02 the induction of pyruvate carboxylase increased the production of succinate 1.7-fold from 1.73 g/L in the control strain to 2.92 g/L. Thus, the succinate increase obtained in the *ldh<sup>-</sup>* mutant strains was significantly lower than that obtained in the wild type strain (MG1655). A possible explanation for this observation might be that pyruvate carboxylase activity was inhibited by a cellular compound which accumulated in the *ldh<sup>-</sup>* mutants.

During glycolysis two moles of reduced nicotinamide adenine dinucleotide (NADH) are generated per mole of glucose. NADH is then oxidized during the formation of ethanol, lactate and succinate under anaerobic conditions. The inability of the *ldh<sup>-</sup>* mutants to consume NADH through lactate formation may put stress on the oxidizing capacity of these strains, leading to an accumulation of NADH. Indeed, this reduced cofactor has previously been shown to inhibit a pyruvate carboxylase isolated from *Saccharomyces cerevisiae* (J. Cazzulo et al., Biochem. J., 112, 755-762 (1969)). In order to elucidate whether such oxidizing stress might be the cause of the attenuated benefit that was observed when pyruvate carboxylase was expressed in the *ldh<sup>-</sup>* mutants, we investigated the effect of both oxidized and reduced nicotinamide adenine dinucleotide (NADH/NAD<sup>+</sup>) and dinucleotide phosphate (NADPH/NADP<sup>+</sup>) on pyruvate carboxylase activity. Enzyme assays were conducted with cell-free crude extract obtained from MG1655 pTrc99A-*pyc*. All assays were conducted in triplicate, and average values are shown in Fig. 9. Standard deviation was no greater than 5% for all data points. NADH inhibited pyruvate carboxylase, whereas NAD<sup>+</sup>, NADP<sup>+</sup> and NADPH did not. The lower succinate enhancement with RE02 the *ldh<sup>-</sup>* mutant is therefore hypothesized to result from

an accumulation of intracellular NADH, a cofactor which appears to inhibit pyruvate carboxylase activity.

### Example III. Expression of *R. etli* Pyruvate Carboxylase

#### 5 Does Not Affect Glucose Uptake in *E. coli* in Anaerobic Fermentation

##### METHODS

**Microorganisms and plasmids.** *E. coli* strain MG1655 (wild type  $F^- \lambda^-$ ; M. Guyer et al., Quant. Biol., Cold Spring Harbor Symp., **45**, 135-140 (1980);  
10 see also Example I) and the plasmid pUC18-*pyc* which contains the *pyc* gene from *R. etli* (see Example I).

**Media and fermentation.** All 2.0 L fermentations were carried out in 2.5 L New Brunswick BioFlo III bench top fermenters (New Brunswick Scientific, Edison, NJ) in Luria-Bertani (LB) supplemented with glucose, 10 g/L;  
15  $\text{Na}_2\text{PHO}_4 \cdot 7\text{H}_2\text{O}$ , 3 g/L;  $\text{KH}_2\text{PO}_4$ , 1.5 g/L;  $\text{NH}_4\text{Cl}$ , 1 g/L;  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 0.25 g/L; and  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ , 0.02 g/L. The fermenters were inoculated with 50 mL of anaerobically grown culture. The fermenters were operated at 150 rpm, 0% oxygen saturation (Ingold polarographic oxygen sensor, New Brunswick Scientific, Edison, NJ), 37°C, and pH 6.4, which was controlled with 10%  
20 NaOH. Anaerobic conditions were maintained by flushing the headspace of the fermenter with oxygen-free carbon dioxide. When necessary, the media was supplemented with an initial concentration of 100 µg/mL ampicillin, previously shown to be sufficient to maintain the selective pressure (Example I).

**Analytical methods.** Cell growth was monitored by measuring the  
25 optical density (OD) (DU-650 spectrophotometer, Beckman Instruments, San Jose, CA) at 600 nm. This optical density was correlated with dry cell mass using a calibration curve of dry cell mass (g/L) = 0.48×OD. Glucose and fermentation products were analyzed by high-pressure liquid chromatography using Coregel 64-H ion-exclusion column (Interactive Chromatography, San  
30 Jose, CA) as described in Example II.

The activity of pyruvate carboxylase and the endogenous activity of PEP carboxylase was measured by growing each strain and clone separately in 160 mL serum bottles under strict anaerobic conditions. Cultures were harvested in mid-logarithmic growth, washed and subjected to cell disruption by sonication.

5 Cell debris were removed by centrifugation ( $20000\times g$  for 15 min at  $4^{\circ}\text{C}$ ). Pyruvate carboxylase activity was measured as previously described (Payne and Morris, 1969), and the PEP carboxylase activity was measured in the absence of ATP using PEP instead of pyruvate as the substrate, with the appearance of CoA-dependent thionitrobenzoate formation at 412 nm monitored. The total

10 protein in the cell extract was determined using the Lowry method.

## RESULTS

*E. coli* MG1655 grew anaerobically with 10 g/L glucose as energy and carbon source to produce the end products shown in Fig. 2. The participation of phosphoenolpyruvate in glucose uptake is shown by the dashed line. The

15 biochemical pathway is not stoichiometric nor are all cofactors shown. Fig. 10 shows the dry cell mass, succinate, lactate, formate and glucose concentrations with time in a typical 2-liter fermentation of this wild-type strain. Fig. 11 shows these concentrations with time in a fermentation of this wild-type strain with the cloning/expression vector pUC18. After complete glucose utilization, the

20 average final concentration of succinate for the wild-type strain was 1.18 g/L, while for the wild-type strain with the vector pUC18 the final succinate concentration was 1.00 g/L. For these fermentations, the average final lactate concentration was 2.33 g/L for the wild-type strain and 2.27 g/L for the same

25 strain with pUC18.

Fig. 12 shows the concentrations with time of dry cell mass, succinate, lactate, formate and glucose in a fermentation of the strain containing the pUC18-*pyc* plasmid. This figure shows that the expression of pyruvate carboxylase causes a substantial increase in final succinate concentration and a

30 decrease in lactate concentration. Specifically, for the wild-type with pUC18-*pyc* the average final succinate concentration was 1.77 g/L, while the average

final lactate concentration was 1.88 g/L. These concentrations correspond to a 50% increase in succinate and about a 20% decrease in lactate concentration, indicating that carbon was diverted from lactate toward succinate formation in the presence of the pyruvate carboxylase.

5 The activities of PEP carboxylase and pyruvate carboxylase were assayed in cell-free extracts of the wild type and the plasmid-containing strains, and these results are shown in Table 5. In the wild type strain and the strain carrying the vector no pyruvate carboxylase activity was detected, while this activity was detected in MG1655/pUC18-*pyc* clone. PEP carboxylase activity was observed  
10 in all three strains.

TABLE 5. Enzyme activity in mid-logarithmic growth culture.

| Strain                   | Sp. activity ( $\mu\text{mol}/\text{min mg protein}$ ) |                 |
|--------------------------|--|-----------------|
|                          | Pyruvate carboxylase                                   | PEP carboxylase |
| MG1655                   | 0.0  | 0.10            |
| MG1655/pUC18             | 0.0  | 0.12            |
| MG1655/pUC18- <i>pyc</i> | 0.06   | 0.08            |

To determine the rates of glucose consumption, succinate production, and cell mass production during the fermentations, each set of concentration data was regressed to a fifth-order polynomial. (These best-fitting curves are shown in  
25 Figs. 10-12 with the measured concentrations.) By taking the first derivative of this function with respect to time, an equation results which provides these rates as functions of time. This procedure is analogous to previous methods (E. Papoutsakis et al., Biotechnol. Bioeng. 27, 56-66 (1985); K. Reardon et al., Biotechnol. Prog. 3, 153-167 (1987)) used to calculate metabolic fluxes. In the  
30 case of fermentations with both pyruvate carboxylase and PEP carboxylase

present, however, the flux analysis cannot be completed due to a mathematical singularity at the PEP/pyruvate nodes (S. Park et al., Biotechnol. Bioeng. 55, 864–879 (1997)). Nevertheless, using this approach the glucose uptake and the rates of succinate and cell mass production may be determined.

5           Table 6 shows the results of calculating the rates of glucose uptake, and succinate and cell mass production in a wild-type *E. coli* strain (MG1655), the wild-type strain with the pUC18 cloning/expression vector (MG1655/pUC18) and the wild-type strain with MG1655/pUC18-*pyc*. All units are g/Lh, and the values in parentheses represent standard deviation of measurements.

TABLE 6. Rates of glucose uptake, succinate production, and cell production.

| Parameter   | MG1655        | MG1655/pUC18  | MG1655/pUC18- <i>pyc</i> |
|---|---------------|---------------|--------------------------|
| Glucose uptake (maximum)                                      | 2.17 (0.10)   | 2.40 (0.01)   | 2.47 (0.01)              |
| Glucose uptake (average during final 4 h of fermentations)    | 1.99 (0.05)   | 2.00 (0.06)   | 1.99 (0.05)              |
| Rate of succinate production (at time of max. glucose uptake) | 0.234 (0.010) | 0.200 (0.012) | 0.426 (0.015)            |
| Rate of succinate production (average during final 4 h)       | 0.207 (0.005) | 0.177 (0.009) | 0.347 (0.002)            |
| Cell production (maximum)                                     | 0.213 (0.006) | 0.169 (0.033) | 0.199 (0.000)            |

- As these results demonstrate, the addition of the cloning vector or the vector with the *pyc* gene had no significant effect on the average glucose uptake during the final 4 hours of the fermentations. Indeed, the presence of the *pyc* gene actually increased the maximum glucose uptake about 14% from 2.17 g/Lh to 2.47 g/Lh.
- 5 The presence of the pUC18 cloning vector reduced slightly the rates of succinate production. As expected from the data shown in Fig. 12, the expression of the *pyc* gene resulted in an 82% increase in succinate production at the time of maximum glucose uptake, and a 68% increase in the rate of succinate production during the final 4 hours of the fermentations. The maximum rate of cell growth (which
- 10 occurred at 4–5 hours for each of the fermentations) was 0.213 g/Lh in the wild type strain, but decreased in the presence of pUC18 (0.169 g/Lh) or pUC18-*pyc* (0.199 g/Lh). Similarly, the overall cell yield was 0.0946 g dry cells/g glucose consumed for the wild-type, but 0.0895 g/g for the wild-type with pUC18 and 0.0882 g/g for the wild-type strain with pUC18-*pyc*. This decrease in biomass may be due to the
- 15 expenditure of one mole of energy unit (ATP) per mole of pyruvate converted to oxaloacetate by pyruvate carboxylase and the increased demands of protein synthesis in the plasmid-containing strains. A specific cell growth rate could not be calculated since the growth of this strain shows logarithmic growth only for the first few hours of growth.
- 20 In summary, expression of pyruvate carboxylase from *R. elli* in *E. coli* causes a significant increase in succinate production at the expense of lactate production without affecting glucose uptake. This result has dramatic ramifications for bacterial fermentation processes which are used to produce oxaloacetate-derived
- biochemicals. Because overexpression of pyruvate carboxylase causes increased
- 25 production of oxaloacetate-derived biochemicals without affecting glucose uptake, this technology can be advantageously employed in fermentation processes in order to obtain more product per amount of inputted glucose.



**Example IV. Expression of *R. etli* Pyruvate Carboxylase Causes Increased  
Threonine Production in *E. coli***

**MATERIALS AND METHODS**

5        **Bacterial strains and plasmids.** The threonine-producing strain  $\beta$ IM-4 (ATCC 21277) was used in this study (Shiio and Nakamori, Agr. Biol. Chem., 33, 1152-1160 (1969); I. Shiio et al. U.S. Pat. No., 3,580,810 (1971)). This strain was transformed with either pTrc99A-pyc (see Example II) or pTrc99A (E. Amann et al., Gene, 69, 301-315 (1988)).

10        **Media and growth conditions.** Aerobic fermentations were carried out in 2.0 L volume in Bioflow II Fermenters. The media used for these fermentation contained (per liter): glucose, 30.0 g;  $(\text{NH}_4)_2\text{SO}_4$  10.0 g,  $\text{FeSO}_4 \cdot \text{H}_2\text{O}$ , 10.0 mg;  $\text{MnSO}_4 \cdot \text{H}_2\text{O}$ , 5.5 mg/L; L-proline, 300 mg; L-isoleucine, 100 mg; L-methionine, 100 mg;  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 1 g;  $\text{KH}_2\text{PO}_4$ , 1 g;  $\text{CaCO}_3$ , 20 g; thiamine-HCl, 1mg; d-biotin, 1  
15 mg. In order to maintain selective pressure for the plasmid-carrying strains, media were supplemented initially with 50 mg/L ampicillin. Also, IPTG was added to a final concentration of 1 mmol/L at 2 hours to fermentations performed with either of these strains.

**Fermentation product analysis.** Cell growth was determined by measuring  
20 optical density at 550 nm of a 1:21 dilution of sample in 0.1M HCl. Glucose, acetic acid and other organic acids were analyzed by high-pressure liquid chromatography as previously described (Eiteman and Chastain, Anal. Chim. Acta, 338, 69-75 (1997)) using a Coregel 64-H ion-exclusion column. Threonine was quantified by  
high-pressure liquid chromatography using the ortho-phthalaldehyde derivatization  
25 method (D. Hill, et al., Anal. Chem., 51, 1338-1341 (1979); V. Svedas, et al. Anal. Biochem., 101, 188-195 (1980)).

**RESULTS**

30        The threonine-producing strain  $\beta$ IM-4 (ATCC 21277), harboring either the control plasmid pTrc99A or the plasmid pTrc99A-pyc which overproduces pyruvate carboxylase, was grown aerobically with 30 g/L glucose as energy and carbon source

and the production of threonine was measured. As shown in Fig. 13, the overproduction of pyruvate carboxylase caused a significant increase in the production of threonine in the threonine-producing *E. coli* strain. At 17 hours when the initial inputted glucose had been consumed, a concentration of 0.57 g/L threonine was detected in the parental strain harboring the pTrc99A control plasmid, while a concentration of 1.37 g/L threonine was detected in the parental strain harboring the pTrc99A-*pyc* plasmid. Given that the final OD<sub>550</sub> of both cultures were within 10% of each other at the end of the fermentation, the 240% increase in threonine concentration caused by the overproduction of pyruvate carboxylase can be deemed to be significant. As in our anaerobic fermentation studies (see Example III), we found that glucose uptake was not adversely affected by the overproduction of pyruvate carboxylase.

#### Example V. Enhanced Synthesis of Lysine by *C. glutamicum*

*C. glutamicum* has long been the preferred microorganism for enzymatic production of lysine in the biochemicals industry. Naturally occurring strains of *C. glutamicum* make more of the oxaloacetate derived amino acids than many other known microbes. See Kirk et al., Encyclopedia of Chemical Technology, 4th Ed., Vol. 2, pp. 534-570 (1992). Strains that are used commercially to make lysine are typically those wherein all biosynthetic branches after oxaloacetate which make any amino acid other than lysine have been knocked out, thus maximizing the biosynthesis of lysine. The enzyme pyruvate carboxylase has only recently been found in *C. glutamicum*, and it does not appear to be highly expressed when *C. glutamicum* is grown on media which uses glucose as the carbon source (P. Peters-Wendisch et al., Mircobiology (Reading), 143, 1095-1103 (1997); M. Koffas et al., GenBank submission number AF038548 (submitted December 14, 1997). Although it contains its own endogenous pyruvate carboxylase, a more convenient way to overexpress this enzyme in *C. glutamicum* is to insert the foreign gene *pyc* from *R. etli*. Accordingly, the current construct from pUC18 as described in Examples I and

II will be transferred into *C. glutamicum* using the shuttle vector pEXO (G. Eikmanns et al., Gene, 102, 93098 (1991)). Overexpression of pyruvate carboxylase in *Corynebacterium glutamicum* can also be achieved using the gene encoding pyruvate carboxylase from *P. fluorescens*. Carbon is expected to be diverted to lysine in an aerobic fermentation and increase lysine yield.

#### Example VI. Enhanced Synthesis of Lysine by *C. glutamicum* Auxotrophs

Recent evidence demonstrates that acetate, valine and alanine each accumulate in the latter stages of lysine synthesis in *C. glutamicum* (J. Vallino et al., Biotechnol. Bioeng., 41, 633-646 (1993)). Since each of these products is derived directly from pyruvate, this observation suggests that a bottleneck exists in the pathway at pyruvate (see Fig. 1). *C. glutamicum* that has been engineered according to the invention to overexpress pyruvate carboxylase already has an additional means of consuming pyruvate, and even more carbon can be diverted to lysine if one or more of these pathways are blocked. Alanine and valine auxotrophs and acetate<sup>-</sup> mutants of *C. glutamicum* can be engineered to overexpress pyruvate carboxylase according to the invention, to further enhance lysine yield.

#### Example VII. Enhanced Synthesis of Threonine in *C. glutamicum*

*C. glutamicum* can also be used to produce threonine, however, the strains that are used for the synthesis of threonine are different from the strains that are used for the synthesis of lysine. In the threonine-producing strains, all biosynthetic branches after oxaloacetate which make any amino acid other than threonine have been knocked out, thus maximizing the biosynthesis of threonine. Since the difference between lysine-producing and threonine-producing strains occurs after the oxaloacetate node, the metabolic engineering technology of the invention can equally be applied to the threonine-producing strains of *C. glutamicum* to enhance threonine synthesis. Synthesis of threonine is further enhanced in a *C. glutamicum*

auxotroph as described above with in Example VI.. relating to lysine synthesis in *C. glutamicum*.

### Example VIII. Enhancement of Biochemical Production

5

#### Using Pyruvate Carboxylase from *P. fluorescens*

One of the main reasons the metabolic network responsible for regulating the intracellular levels of oxaloacetate is so tightly controlled is due to the fact that the key enzymes which are involved in this process are both positively and negatively regulated. In most organisms such as *R. etli*, pyruvate carboxylase requires the positive effector molecule acetyl coenzyme A for its activation and is repressed due to feedback inhibition by aspartate (P. Attwood, Intl. J. Biochem. Cell Biol., 27, 231-249 (1995); M. Dunn et al., J. Bacteriol., 178, 5960-5970 (1996)). The benefits obtained from overproducing *R. etli* pyruvate carboxylase are thus limited by the fact that diverting carbon from pyruvate to oxaloacetate both depletes acetyl coenzyme A levels and increases aspartate levels. The pyruvate carboxylase from *P. fluorescens*, however, does not require acetyl coenzyme A for its activation and it is not affected by the feedback inhibition caused by aspartate (R. Silvia et al., J. Gen. Microbiol., 93, 75-81 (1976)). Overproduced *P. fluorescens* pyruvate carboxylase should allow even more carbon flow to be diverted towards oxaloacetate.

Because the genes encoding pyruvate carboxylases in bacteria appear to be highly homologous, the *P. fluorescens* *pyc* gene may be readily isolated from a genomic library using probes which have been prepared from the *R. etli* gene. The gene for pyruvate carboxylase in *P. fluorescens* will thus be identified, isolated, and cloned into an expression vector using standard genetic engineering techniques. Alternatively, the pyruvate carboxylase enzyme can be isolated and purified from *P. fluorescens* by following pyruvate carboxylase activity (as described in the above Examples) and also by assaying for biotinylated protein using Western blots. The N-terminal amino acid sequence of the purified protein is determined, then a degenerate oligonucleotide probe is made which is used to isolate the gene encoding

pyruvate carboxylase from a genomic library that has been prepared from *P. fluorescens*. The *pyc* clone thus obtained is sequenced. From the sequence data, oligonucleotide primers are designed that allow cloning of this gene into an expression vector so that pyruvate carboxylase can be overproduced in the host cell.

- 5 Either method can be used to yield a vector encoding the *P. fluorescens pyc* gene, which is then used to transform the host *E. coli* or *C. glutamicum* cell. Pyruvate carboxylase from *P. fluorescens* is expressed in the host cell, and biochemical production is enhanced as described in the preceding examples.

10 **Example IX. Enhancement of Biochemical Production**  
**By Overexpression of Both Pyruvate Carboxylase and PEP Carboxylase**

- In many organisms PEP can be carboxylated to oxaloacetate via PEP carboxylase or it can be converted to pyruvate by pyruvate kinase (I. Shii et al., J. Biochem., 48, 110-120 (1960); M. Jetten et al., Appl. Microbiol. Biotechnol., 41, 47-52 (1994)). One possible strategy that was tried to increase the carbon flux toward oxaloacetate in *C. glutamicum* was to block the carbon flux from PEP toward pyruvate (see Fig. 3). However, lysine production by pyruvate kinase mutants was 40% lower than by a parent strain, indicating that pyruvate is essential for high-level
- 20 lysine production (M. Gubler et al., Appl. Microbiol. Biotechnol., 60, 47-52 (1994)).

Carbon flux toward oxaloacetate may be increased by overexpressing PEP carboxylase in conjunction with overexpressed pyruvate carboxylase without concomitantly blocking carbon flux from PEP to pyruvate or affecting glucose uptake.

- 25 In heterotrophs such as *C. glutamicum*, however, PEP carboxylase requires acetyl-CoA for its activation, and is inhibited by aspartate (S. Mike et al., Annals NY Acad. Sci., 272, 12-29 (1993)); hence amplification of *C. glutamicum* PEP carboxylase genes has not resulted in increased lysine yield (J. Kremer et al., Appl. Environ. Microbiol., 57, 1746-1752 (1991)). PEP carboxylase isolated from the
- 30 cyanobacteria *Anacystis nidulans*, however, does not require acetyl CoA for

activation nor is it inhibited by aspartate (M. Utter et al., Enzymes, 6, 117-135 (1972)). Therefore, this heterologous enzyme can be used to increase the carbon flux towards oxaloacetate in *C. glutamicum*. The genes encoding PEP carboxylase in *A. nidulans* have been isolated and cloned (T. Kodaki et al., J. Biochem., 97, 533-539 (1985)).

**Example X. Enhancement of Biochemical Production By Disrupting the *pck* Gene Encoding PEP Carboxykinase in Conjunction with Overexpressed Pyruvate Carboxylase**

10

Some of carbon which is diverted to oxaloacetate via overproduced pyruvate carboxylase is likely converted back to PEP due to the presence of PEP carboxykinase. More carbon can be diverted towards oxaloacetate in these systems if the host cell contains a disrupted *pck* gene, such as an *E. coli* strain which contains a *pck* null allele (e.g., A. Goldie, J. Bacteriol., 141, 1115-1121 (1980)).

15

The complete disclosure of all patents, patent documents, and publications cited herein are incorporated by reference. The foregoing detailed description and examples have been given for clarity of understanding only. No unnecessary limitations are to be understood therefrom. The invention is not limited to the exact details shown and described, for variations obvious to one skilled in the art will be included within the invention defined by the claims.

20

## WHAT IS CLAIMED IS:

1. A metabolically engineered cell comprising pyruvate carboxylase, wherein the metabolically engineered cell overexpresses pyruvate carboxylase.
2. The metabolically engineered cell of claim 1 which is a bacterial cell.
3. The bacterial cell of claim 2 which is selected from the group consisting of a *Corynebacterium glutamicum* cell, an *Escherichia coli* cell, a *Brevibacterium flavum* cell and a *Brevibacterium lactofermentum* cell.
4. The bacterial cell of claim 3 which is a *C. glutamicum* cell.
5. The *C. glutamicum* cell of claim 4 having at least one of the mutations selected from the groups consisting of alanine<sup>-</sup>, valine<sup>-</sup> and acetate<sup>-</sup>.
6. The bacterial cell of claim 3 which is an *E. coli* cell.
7. The metabolically engineered cell of claim 1 which expresses pyruvate carboxylase at a level higher than the level of pyruvate carboxylase expressed in a comparable wild-type cell.
8. The metabolically engineered cell of claim 1 that expresses a pyruvate carboxylase derived from *Rhizobium etli*.
9. The metabolically engineered cell of claim 8 that has been transformed with a *pyc* gene of *R. etli*.
10. The metabolically engineered cell of claim 1 that expresses a pyruvate carboxylase derived from *Pseudomonas fluorescens*.

11. The metabolically engineered cell of claim 10 that has been transformed with a *pyc* gene of *P. fluorescens*.
12. The metabolically engineered cell of claim 7 wherein the comparable wild-type cell does not express a pyruvate carboxylase.
13. The metabolically engineered cell of claim 1 further comprising PEP carboxylase, wherein the metabolically engineered cell overexpresses PEP carboxylase.
14. The metabolically engineered cell of claim 13 that expresses PEP carboxylase derived from *Anacystis nidulans*.
15. The metabolically engineered cell of claim 1 further comprising PEP carboxykinase, wherein the metabolically engineered cell expresses PEP carboxykinase at a level lower than the level of PEP carboxykinase expressed in the comparable wild-type cell.
16. The metabolically engineered cell of claim 15 which does not express a detectable level of PEP carboxykinase.
17. A *C. glutamicum* cell comprising a heterologous pyruvate carboxylase.
18. An *E. coli* cell comprising pyruvate carboxylase.
19. A method for making a metabolically engineered cell comprising transforming a cell with a nucleic acid fragment comprising a nucleotide sequence encoding an enzyme having pyruvate carboxylase activity to yield a metabolically engineered cell that overexpresses pyruvate carboxylase.



20. The method of claim 19 wherein the cell that is transformed is a bacterial cell.
21. The method of claim 20 wherein the bacterial cell is selected from the group consisting of a *C. glutamicum* cell, an *E. coli* cell, a *B. flavum* cell and a *B. lactofermentum* cell.
22. The method of claim 21 wherein the bacterial cell is a *C. glutamicum* cell.
23. The method of claim 21 wherein the bacterial cell is an *E. coli* cell.
24. The method of claim 19 wherein the nucleic acid fragment comprises a nucleotide sequence selected from the group consisting of a *R. etli* gene encoding pyruvate carboxylase and a *P. fluorescens* gene encoding pyruvate carboxylase.
25. The method of claim 19 further comprising transforming the cell with a nucleic acid fragment comprising a nucleotide sequence encoding PEP carboxylase such that metabolically engineered cell overexpresses PEP carboxylase.
26. The method of claim 19 wherein the metabolically engineered cell does not express a detectable level of PEP carboxykinase.
27. The method of claim 19 wherein the metabolically engineered cell expresses pyruvate carboxylase at a level higher than the level of pyruvate carboxylase expressed in a comparable wild-type cell.
28. A method for making a metabolically engineered cell comprising mutating a gene of a cell, said gene encoding an enzyme having pyruvate carboxylase activity, to yield a metabolically engineered cell that overexpresses pyruvate carboxylase.

29. The method of claim 28 wherein the cell is a bacterial cell.
30. The method of claim 29 wherein the cell is a *C. glutamicum* cell.
31. A method for making an oxaloacetate-derived biochemical comprising:
  - (a) providing a cell that produces the biochemical;
  - (b) transforming the cell with a nucleic acid fragment comprising a nucleotide sequence encoding an enzyme having pyruvate carboxylase activity;
  - (c) expressing the enzyme in the cell to cause increased production of the biochemical; and
  - (d) isolating the biochemical from the cell.
32. The method of claim 31 wherein step (a) comprises providing a bacterial cell that produces the biochemical.
33. The method of claim 32 wherein the bacterial cell is selected from the group consisting of a *C. glutamicum* cell, an *E. coli* cell, a *B. flavum* cell and a *B. lactofermentum*.
34. The method of claim 33 wherein the bacterial cell is an *E. coli* cell.
35. The method of claim 33 wherein the bacterial cell is *C. glutamicum* cell.
36. The method of claim 31 wherein the nucleic acid fragment comprises a nucleotide sequence selected from the group consisting of an *R. etli* gene encoding pyruvate carboxylase and a *P. fluorescens* gene encoding pyruvate carboxylase.
37. The method of claim 31 wherein the oxaloacetate-derived biochemical is selected from the group consisting of an organic acid, an amino acid, a porphyrin and a pyrimidine nucleotide.

38. The method of claim 31 wherein the oxaloacetate-derived biochemical is selected from the group consisting of arginine, asparagine, aspartate, glutamate, glutamine, methionine, threonine, proline, isoleucine, lysine, malate, fumarate, succinate, citrate, isocitrate,  $\alpha$ -ketoglutarate and succinyl-CoA.
39. The method of claim 38 wherein the oxaloacetate-derived biochemical is lysine.
40. The method of claim 38 wherein the oxaloacetate-derived biochemical is succinate.
41. The method of claim 38 wherein the oxaloacetate-derived biochemical is threonine.
42. A method for making an oxaloacetate-derived biochemical comprising:  
(a) providing a cell that produces the biochemical;  
(b) mutating a gene of a cell, said gene encoding an enzyme having pyruvate carboxylase activity;  
(c) overexpressing the enzyme from the mutated gene to cause increased production of the biochemical; and  
(d) isolating the biochemical from the cell.
43. The method of claim 42 wherein step (a) comprises providing a bacterial cell that produces the biochemical.
44. The method of claim 43 wherein the bacterial cell is a *C. glutamicum* cell.
45. The method of claim 42 wherein the oxaloacetate-derived biochemical is selected from the group consisting of an organic acid, an amino acid, a porphyrin and a pyrimidine nucleotide.

46. The method of claim 45 wherein the oxaloacetate-derived biochemical is selected from the group consisting of arginine, asparagine, aspartate, glutamate, glutamine, methionine, threonine, proline, isoleucine, lysine, malate, fumarate, succinate, citrate, isocitrate,  $\alpha$ -ketoglutarate and succinyl-CoA.

47. The method of claim 46 wherein the oxaloacetate-derived biochemical is lysine.

48. The method of claim 46 wherein the oxaloacetate-derived biochemical is succinate.

49. The method of claim 46 wherein the oxaloacetate-derived biochemical is threonine.

50. A nucleic acid fragment isolated from *P. fluorescens* comprising a nucleotide sequence encoding a pyruvate carboxylase.

1/13






FIG. 1


2/13

**FIG. 2**

3/13


**FIG. 3**

4/13


**FIG. 4**




5/13

**FIG. 5**


5/13

**FIG. 5**


6/13

**FIG. 6**

7/13


**FIG. 7**

8/13




**FIG. 8**


9/13

**FIG. 9**

10/13


**FIG. 10**

11/13


**FIG. 11**



12/13

**FIG. 12**

13/13

**FIG. 13**

# INTERNATIONAL SEARCH REPORT

national Application No  
PCT/US 99/08014

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 C12N9/00 C12P13/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.                        |
|------------|--|--|
| X          | PETERS-WENDISCH, P.G. ET AL.: "Pyruvate carboxylase from Corynebacterium glutamicum: ..."<br>MICROBIOLOGY,<br>vol. 144, April 1998 (1998-04), pages 915-927, XP002111327               | 1-4,6,7,<br>12,15,<br>16,<br>18-23,<br>26-30 |
| Y          | * summary; p. 916, 923-925; figs. 1,2,5 *  | 1-50   |
| Y          | ---<br>PINES, O. ET AL.: "Overexpression of cytosolic malate dehydrogenase ..."<br>APPL. MICROBIOL. BIOTECHNOL.,<br>vol. 48, 1997, pages 248-255, XP002111328<br>* pages 248 and 254 * | 1-50   |
| Y          | ---<br>EP 0 723 011 A (AJINOMOTO CO., INC.)<br>24 July 1996 (1996-07-24)<br>* p. 1-11; claims *  | 13-16,<br>25,26                              |
|            | ---<br>-/--  |  |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

**\* Special categories of cited documents:**

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

4 August 1999

Date of mailing of the international search report

01/09/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Hermann, R

## INTERNATIONAL SEARCH REPORT

National Application No  
PCT/US 99/08014

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| Y          | CHEMICAL ABSTRACTS, vol. 126, no. 12,<br>24 March 1997 (1997-03-24)<br>Columbus, Ohio, US;<br>abstract no. 154946,<br>XP002111333<br>* abstract *<br>& PETERS-WENDISCH, P.: "Anaplerotic<br>reactions in Corynebacterium glutamicum<br>..."<br>BER. FORSCHUNGSZENT. JUELICH, 1996, pages<br>1-121,<br>--- | 1-50                  |
| Y          | MILRAD DE FORCHETTI, S.R. & CAZZULO, J.J.:<br>"Some properties of the Pyruvate<br>Carboxylase from Pseudomonas fluorescens"<br>J. GEN. MICROBIOL.,<br>vol. 93, 1976, pages 75-81, XP002111329<br>* summary *  | 10, 11,<br>36, 50     |
| A          | WALLACE, J.C. ET AL.: "Pyruvate<br>carboxylase"<br>INT. J. BIOCHEM. CELL BIOL.,<br>vol. 30, January 1998 (1998-01), pages<br>1-5, XP002111330<br>* summary; p.1; fig. 2 *   | 1-50                  |
| P, X       | GOKARN, R.R. ET AL.: "Expression of<br>pyruvate carboxylase ..."<br>BIOTECHNOLOGY LETTERS,<br>vol. 20, no. 8, August 1998 (1998-08),<br>pages 795-798, XP002111331<br>* whole disclosure *  | 1-50                  |
| P, X       | EITEMAN, M.A. ET AL.: "expression of<br>pyruvate carboxylase ..."<br>ABSTRACTS OF PAPERS AM. CHEM. SOC.,<br>vol. 217, no. 1-2, 1999, XP002111332<br>* abstract BIOT 031 of 217th meeting of<br>the Am. Chem. Soc, March 21-25, 1999 *   | 1-50                  |
| E          | WO 99 18228 A (FORSCHUNGSZENTRUM JÜLICH<br>GMBH) 15 April 1999 (1999-04-15)<br>* pages 1-7; claims *  | 1-50                  |

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/08014

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

National Application No

PCT/US 99/08014

| Patent document<br>cited in search report |   | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---|---------------------|----------------------------|---------------------|
| EP 723011                                 | A | 24-07-1996          | AU 682547 B                | 09-10-1997          |
|   |   |                     | AU 8099194 A               | 21-03-1995          |
|   |   |                     | BR 9407625 A               | 21-01-1997          |
|   |   |                     | PL 313119 A                | 10-06-1996          |
|   |   |                     | SK 20496 A                 | 06-11-1996          |
|   |   |                     | US 5876983 A               | 02-03-1999          |
|   |   |                     | CA 2169170 A               | 02-03-1995          |
|   |   |                     | CN 1133615 A               | 16-10-1996          |
|   |   |                     | CZ 9600524 A               | 12-06-1996          |
|   |   |                     | HU 73690 A                 | 30-09-1996          |
|   |   |                     | WO 9506114 A               | 02-03-1995          |
|   |   |                     | JP 7111890 A               | 02-05-1995          |
|   |   |                     | JP 8070860 A               | 19-03-1996          |
| WO 9918228                                | A | 15-04-1999          | DE 19831609 A              | 15-04-1999          |
|   |   |                     | AU 1148299 A               | 27-04-1999          |